5PSQ-048 Darunavir/cobicistat pharmacological interactions: clinical relevance and action mechanism

BACKGROUND: Darunavir/cobicistat (DRV/COB) is the first fixed combination inhibitor of protease. Both are metabolised by the cytochrome CYP3A4, the reason why they are susceptible to present a multitude of drug interactions (DI). PURPOSE: To describe the DI of DRV/COB in HIV patients to avoid and to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Hosp Pharm
Autors principals: Cabrera, F Avila, Romacho, J Urda, Peralta, A Jofre, Vaquero, D Gonzalez, Garcia, M Aznar, Rosa, A Martos, de la Plata, JE Martinez, Robles, P Acosta, Molina, JA Morales, Vida, MACastro
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2018
Matèries:
Section 5: Patient safety and quality assurance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535842/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.402
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars